Ocumension Therapeutics (HK:1477)
:1477
Want to see HK:1477 full AI Analyst Report?
Total Valuation
Ocumension Therapeutics has a market cap or net worth of HK$5.90B. The enterprise value is HK$4.86B.
Market CapHK$5.90B
Enterprise ValueHK$4.86B
Share Statistics
Ocumension Therapeutics has 836,331,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding836,331,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ocumension Therapeutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -4.00%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-4.00%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee1.60M
Profits Per Employee-324.07K
Employee Count489
Asset Turnover0.19
Inventory Turnover6.89
Valuation Ratios
The current PE Ratio of Ocumension Therapeutics is ―. Ocumension Therapeutics’s PEG ratio is 0.70.
PE Ratio―
PS Ratio6.74
PB Ratio1.43
Price to Fair Value1.43
Price to FCF-14.72
Price to Operating Cash Flow-49.11
PEG Ratio0.70
Income Statement
In the last 12 months, Ocumension Therapeutics had revenue of 783.53M and earned -154.71M in profits. Earnings per share was -0.20.
Revenue783.53M
Gross Profit343.08M
Operating Income-156.06M
Pretax Income-154.37M
Net Income-154.71M
EBITDA-147.56M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -160.92M and capital expenditures -34.15M, giving a free cash flow of -195.07M billion.
Operating Cash Flow-160.92M
Free Cash Flow-195.07M
Free Cash Flow per Share-0.23
Dividends & Yields
Ocumension Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change34.57%
50-Day Moving Average7.27
200-Day Moving Average8.42
Relative Strength Index (RSI)62.68
Average Volume (3m)3.41M
Important Dates
Ocumension Therapeutics upcoming earnings date is Aug 20, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateAug 20, 2026
Ex-Dividend Date―
Financial Position
Ocumension Therapeutics as a current ratio of 3.70, with Debt / Equity ratio of 5.10%
Current Ratio3.70
Quick Ratio3.46
Debt to Market Cap0.03
Net Debt to EBITDA1.46
Interest Coverage Ratio-65.52
Taxes
In the past 12 months, Ocumension Therapeutics has paid 340.94K in taxes.
Income Tax340.94K
Effective Tax Rate>-0.01
Enterprise Valuation
Ocumension Therapeutics EV to EBITDA ratio is -34.31, with an EV/FCF ratio of -14.12.
EV to Sales6.46
EV to EBITDA-34.31
EV to Free Cash Flow-14.12
EV to Operating Cash Flow-48.09
Balance Sheet
Ocumension Therapeutics has HK$578.27M in cash and marketable securities with HK$83.22M in debt, giving a net cash position of HK$495.05M billion.
Cash & Marketable SecuritiesHK$578.27M
Total DebtHK$83.22M
Net CashHK$495.05M
Net Cash Per ShareHK$0.59
Tangible Book Value Per ShareHK$1.36
Margins
Gross margin is 44.82%, with operating margin of -19.92%, and net profit margin of -19.75%.
Gross Margin44.82%
Operating Margin-19.92%
Pretax Margin-19.70%
Net Profit Margin-19.75%
EBITDA Margin-18.83%
EBIT Margin-19.92%
Analyst Forecast
The average price target for Ocumension Therapeutics is HK$10.16, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$10.16
Price Target Upside34.57% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast93.26%
EPS Growth Forecast49.33%